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Introduction
Percutaneous nephrolithotomy (PCNL) is the preferred treatment modality for renal stones greater than 2 cm in diameter, including staghorn calculi (1) . PCNL success rates, defined as patients rendered stone free on post-operative imaging, range from 75-90% (2-4).
The efficiency of the intracorporeal lithotripter device, the instrument used to remove the majority of the stone burden, is essential to successful stone clearance. 
Materials and methods

Study design and participants
We conducted a prospective, multicenter, randomized, controlled trial with nine participating sites across North America ( This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
LUS-II (Olympus, Melville, NY) lithotripter in this trial. The LUS-II was used only after stone fragmentation by the StoneBreaker was achieved and larger pieces were already removed using graspers. It was used primarily to suction up smaller fragments rather than to fragment the main stone. Clearance rate was calculated by dividing the surface area of the targeted stone (mm 2 ) by the total clearance time (min). Other study parameters including number and location of accesses, anesthesia type, blood loss, drainage type, length of stay, transfusion rates, secondary procedures, and complications were also recorded.
Stone free rate (a secondary study outcome) was defined as no visible fragments. It was determined either by visualization at secondary nephroscopy or a CT scan within 30 days of the initial procedure. Secondary nephroscopy was employed as a surrogate of stone free rate since only patients who harbor residual stones on postoperative imaging (typically a CT scan) would be offered this procedure. Stone composition was recorded as the predominant component on stone analysis. Except for the use of a specific lithotripter they were randomized to, the management of the patients in this trial did not otherwise differ from the standard PCNL operation.
Outcomes
The primary study outcome was target stone clearance time in minutes. Stone size variability was larger than expected so an additional outcome of clearance rate (mm 2 /min) was added. To calculate stone clearance rate, the target stone surface area was divided by the stone clearance time. Secondary outcomes were stone free rate (assessed as described above), secondary procedures rate, complications, and length of stay.
Statistical analysis
Sample size calculations were performed by a biostatistician using a two-sided, twosample Student t-test. Since comparisons were made between all three treatment groups, the significance level used to determine the sample size was adjusted. For simplicity, the Bonferroni method was employed (i.e. α = 0.05/3 = 0.017). The primary outcome of interest was the stone clearance time (min). From previous experience in a similar study at our institution, the mean clearance time for stones between 500 mm 3 and 1000 mm 3 using the Olympus LUS-II was found to be 13. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
expected in our trial. Assuming one of the other study groups has a true stone clearance time that is 25% different than the Olympus LUS-II, then 70 subjects in each group were required to provide 82% power to detect that difference. A total of 210 subjects were needed, 70 into each treatment group. Each arm of the study could enroll up to 90 subjects for a total of up to 270 subjects across all sites to obtain 210 completed subjects.
Each individual site was allowed to enroll up to 75 subjects.
Statistical analysis was performed using Minitab 14. project.org/). All subject demographics were summarized by experimental group using descriptive statistics and tabulated. Continuous demographic variables were compared across study groups using analysis of variance (ANOVA). Categorical demographic variables were compared using Pearson Chi-square tests. The mean stone clearance time was determined for each experimental group. Mean times were compared across groups using ANOVA. To investigate pairwise differences between individual groups, Tukey's HSD post hoc test was used. Continuous measures were summarized using mean (standard deviation, SD) or median (min, max) and compared across groups using ANOVA.
Categorical measures were summarized using frequency (percent) and compared across groups using Fisher's Exact test.
Results
A total of 270 patients were enrolled and randomized at 9 sites from October of 2009 to This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
The mean patient age was 57 years (range 20-89 years) and 104/201 (52%) were female.
Patients were well matched on baseline characteristics in the three treatment groups, as detailed in Table 3 . However, the stone surface area was significantly lower in the was used to compare the rates across groups while adjusting for stone size. After adjusting for smaller average stone size in the StoneBreaker cohort, there was no significant difference in stone clearance rates between the three devices (p=0.249, Table   4 ).
Secondary outcomes, including intra-operative or post-operative complications and stone free rates were similar between the groups. There were no statistically significant differences in the rates of stent placement, nephrostomy tube placement, use of other devices, reported intraoperative complications, estimated blood loss (EBL) > 400ml, red blood cell (RBC) transfusion rates, and the average length of stay. Of the intraoperative complications reported, bleeding (6 patients, 3%) and collecting system perforation (7 patients, 3.5%) were the most common. Post-operatively, fever (6 patients, 3%), pleural effusion or pneumothorax (5 patients, 2.5%), and sepsis (3 patients, 1.5%) were the most commonly reported complication. Secondary outcomes are further detailed in Table 5 .
The stone free rate following the primary PCNL procedure, defined as no visible stones on post-operative CT scan, averaged 58% with no significant difference between the three groups (p=0.277). Stone composition was similar in the three groups. The clearance rate of "hard" stones (defined as brushite, cystine, and uric acid stones) was comparable across This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Discussion
Lithotripter efficiency is a crucial component of a rapid and successful PCNL procedure.
We studied three modern lithotripters to determine stone clearance efficiency in a clinical setting using a randomized controlled trial design to minimize the risk of bias. To allow for fair comparison of devices, StoneBreaker was used in combination with an ultrasonic lithotripter (LUS-II) since the StoneBreaker lacks ultrasonic capability of its own. We included time spent retrieving target stone fragments in the overall treatment time to ensure assessment of true stone clearance and not just the fragmentation time alone.
While there appeared to be differences in the clearance rate between groups, after taking into account the variation in stone sizes between groups, we did not find a statistically significant difference between the three devices. The study demonstrated equivalent safety and efficacy of the three devices. There were no significant differences in stone free status and intra-operative or post-operative complications. Our findings should be taken into account when considering the purchase of costly lithotripter equipment. Since the device efficiency, as assessed by stone clearance rates, is similar, other factors become more important in choosing a specific lithotripter device. These factors include ergonomics, durability, cost of disposable pieces, and contracts with vendors (Table 6 ). For example, a strategy to reduce cost might be to use an ultrasonic device such as LUS-2 lithotripter initially (reusable parts) for the majority of stones, with the addition of the StoneBreaker for pneumatic fragmentation of particularly hard stones only. In most situations, this would eliminate the need for the routine use of expensive disposables.
Some of the advantages and disadvantages of the three devices are outlined in Table 7 .
Previous studies have compared several lithotripters. Krambeck et al found no difference in stone clearance rate between the Olympus LUS-II and Cyberwand lithotripters in a randomized trial (7) . In another trial, Chew et al found StoneBreaker to be superior to the Swiss Lithoclast (8) . The Lithoclast Ultra was found to be significantly faster than the LUS-II in a study by Pietrow et al (9) . El-Nahas et al compared an ultrasonic lithotripter This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
America to make this study the largest randomized controlled trial to date on this subject and the first comparing Cyberwand, Lithoclast Select, and the StoneBreaker directly. The outcomes we report may not be reproducible in a lower volume, smaller center without the same operating room resources and staff experience in lithotripsy.
One unexpected finding in our study is the significantly smaller mean stone surface area in the StoneBreaker group. This result is difficult to explain as our study protocol included randomization, thereby controlling for the stone size variable. We carefully reviewed our primary data to identify possible reasons for this finding. Study authors checked individual patient data with regard to stone size. No obvious systemic data entry error existed to explain the smaller stone size in StoneBreaker group. The patients were randomized from a central location making bias from one of the treatment sites to use a particular device for smaller stones unlikely. The reasons for patient exclusion after randomization were similar across the three study groups (Figure 4 ). Given the smaller average stone size in the StoneBreaker group, statistical adjustments were necessary to compare efficacy of treatment. We used analysis of covariance (ANCOVA) to adjust for stone size and found no significant difference in clearance rate between the three groups (p=0.249, Table 4 ).
Despite the differences in average surface area, we feel this adjustment would make for a fair comparison between the devices.
Another limitation of our study is that it is slightly underpowered. A total of 201 patients, with 71, 66, and 64 patients in the Cyberwand, Lithoclast Select, and StoneBreaker treatment groups respectively, completed the study. Our study was powered for 70 patients in each arm. To allow for possible exclusions, 270 patients were randomized.
Slightly more than anticipated patients were excluded after randomization resulting in marginally underpowered study. As detailed in Table 4 , clearance time and adjusted clearance rate were not significantly different between the treatment groups. It is possible (but unlikely) that the underpowered sample size is responsible for the finding of no difference between the study groups. A larger target stone size might also have helped differentiate lithotripters, albeit at the expense of reduced study participant numbers. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. Downloaded by Indiana Univ Acq Dept from online.liebertpub.com at 09/05/17. For personal use only.
